Følg
Uffe Klausen
Uffe Klausen
Rigshospitalet
Verificeret mail på regionh.dk
Titel
Citeret af
Citeret af
År
High frequencies of circulating memory T cells specific for calreticulin exon 9 mutations in healthy individuals
MO Holmström, SM Ahmad, U Klausen, SK Bendtsen, E Martinenaite, ...
Blood cancer journal 9 (2), 8, 2019
332019
The inhibitory checkpoint, PD-L2, is a target for effector T cells: Novel possibilities for immune therapy
SM Ahmad, E Martinenaite, M Holmström, MA Jørgensen, Ö Met, ...
Oncoimmunology 7 (2), e1390641, 2018
332018
Therapeutic cancer vaccination with a peptide derived from the calreticulin exon 9 mutations induces strong cellular immune responses in patients with CALR-mutant chronic …
J Handlos Grauslund, MO Holmström, NG Jørgensen, U Klausen, ...
Frontiers in Oncology 11, 637420, 2021
322021
Novel strategies for peptide-based vaccines in hematological malignancies
U Klausen, S Holmberg, MO Holmström, NGD Jørgensen, JH Grauslund, ...
Frontiers in immunology 9, 2264, 2018
252018
Peptide vaccination against PD-L1 with IO103 a novel immune modulatory vaccine in multiple myeloma: a phase I first-in-human trial
NG Jørgensen, U Klausen, JH Grauslund, C Helleberg, TG Aagaard, ...
Frontiers in Immunology 11, 595035, 2020
192020
Cancer immune therapy for lymphoid malignancies: recent advances
U Klausen, NGD Jørgensen, JH Grauslund, MO Holmström, MH Andersen
Seminars in immunopathology 41, 111-124, 2019
162019
An arginase1-and PD-L1-derived peptide-based vaccine for myeloproliferative neoplasms: A first-in-man clinical trial
JH Grauslund, MO Holmström, E Martinenaite, TL Lisle, HJ Glöckner, ...
Frontiers in Immunology 14, 1117466, 2023
32023
An immunogenic first-in-human immune modulatory vaccine with PD-L1 and PD-L2 peptides is feasible and shows early signs of efficacy in follicular lymphoma
U Klausen, N Grønne Dahlager Jørgensen, JH Grauslund, ...
OncoImmunology 10 (1), 1975889, 2021
12021
Anti-PD-L1/PD-L2 therapeutic vaccination in untreated chronic lymphocytic leukemia patients with unmutated IgHV
U Klausen, JH Grauslund, NGD Jørgensen, SM Ahmad, M Jonassen, ...
Frontiers in Oncology 12, 1023015, 2022
2022
Peptide vaccination in chronic lymphoproliferative malignancies: Targeting PDL1 and PDL2 in follicular lymphoma and chronic lymphocytic leukemia
U Klausen
University of Copenhagen, 2022
2022
Therapeutic cancer vaccination for treatment of haematological cancers
MO Holmström, JH Grauslund, NG Dahlager-Jørgensen, U Klausen, ...
Ugeskrift for Laeger 181 (20A), 2019
2019
PS1380 PEPTIDE VACCINATION AGAINST PD-L1 (IO103) IN MULTIPLE MYELOMA–A PHASE I FIRST IN HUMAN TRIAL
NG Jørgensen, SM Ahmad, U Klausen, JH Grauslund, M Hansen, ...
HemaSphere 3 (S1), 631-632, 2019
2019
Cancer immune therapy for the treatment of haematological malignancies
MO Holmström, U Klausen, NG Jørgensen, S Holmberg, J Grauslund, ...
Ugeskrift for Laeger 181 (10), 2019
2019
Cancerimmunterapi til behandling af hæmatologisk cancer
KA T-CELLER
Ugeskr Læger 181, V06180421, 2019
2019
Mikromiljøet som med-og modspiller i B-celle-non-Hodgkin-lymfomer
U Klausen, MH Andersen, LM Pedersen
Ugeskrift for læger 26 (2017; 179: V03170220), 2-6, 2017
2017
Micro-environment being agonist as well as antagonist in B-cell non-Hodgkin lymphoma pathology
U Klausen, MH Andersen, LM Pedersen
Ugeskr Læger, 2-6, 2017
2017
Systemet kan ikke foretage handlingen nu. Prøv igen senere.
Artikler 1–16